后COVID认知功能障碍:高风险人群的现状和研究建议
Meina Quan1,2, Xuechu Wang1, Min Gong1
1Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, China.
The Lancet regional health. Western Pacific
|July 17, 2023
概括
后COVID认知功能障碍 (PCCD) 涉及SARS-CoV-2感染后的认知障碍. 需要进行研究,以确定风险因素,并制定有效的预防和管理策略.
科学领域:
- 神经学 神经学
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 后COVID认知功能障碍 (PCCD) 是SARS-CoV-2感染后的一个显著的神经并发症.
- 具有多个领域认知功能受损的特征,PCCD在感染后大约三个月呈现,不能归因于其他诊断.
- 目前对PCCD的风险因素和管理的理解仍然有限,需要对其研究采取综合方法.
研究的目的:
- 审查和综合目前关于PCCD流行病学,诊断标志物,风险因素和治疗方法的证据.
- 建立共识标准,以便更好地理解和管理PCCD.
- 制定一个研究建议框架,用于识别和支持受PCCD影响的弱势群体.
主要方法:
- 关于后COVID认知功能障碍研究的综合文献综述.
- 对流行病学数据,诊断标志物和确定的风险因素的分析.
- 评估现有的治疗策略,并制定管理建议.
主要成果:
- 该审查综合了PCCD的现有数据,突出了关于其病因和进展的知识差距.
- 确定了需要进一步调查的关键风险因素和脆弱人群.
- 总结了当前的治疗方法及其局限性.
结论:
- PCCD是一种已知的后感染性神经疾病,需要进一步研究才能有效治疗.
- 达成共识的标准和有针对性的研究框架对于促进PCCD的理解和治疗至关重要.
- 解决PCCD对于改善后COVID时代患者的治疗结果至关重要.
相关概念视频
01:30Cognitive Development During Adulthood
160
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
160
01:28Acute Coronary Syndrome IV: Interprofessional Care
12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12
01:26Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
21
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
21
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
159
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
159